NCT01804530View on ClinicalTrials.gov

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 24, 2018

Study Completion Date

January 24, 2018

Conditions
Solid TumorTumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion MutationsTenosynovial Giant Cell Tumor
Interventions
DRUG

PLX7486 TsOH

PLX7486 TsOH capsules, 50mg

Trial Locations (4)

21231

John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

29425

Medical University of South Carolina, Charleston

90095

Ronald Reagan UCLA Medical Center, Los Angeles

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Lead Sponsor

Plexxikon
All Listed Sponsors
lead

Plexxikon

INDUSTRY

NCT01804530 - Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter